Inventiva SA
IVA3.350USD
+0.130+4.04%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
0.00Valor de mercado
--P/L TTM
Mais detalhes de Inventiva SA Empresa
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Informações da empresa
Código da empresaIVA
Nome da EmpresaInventiva SA
Data de listagemFeb 15, 2017
CEOMr. Frederic Cren
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscal- -
Endereço50 rue de Dijon
CidadeDAIX
Bolsa de valoresEuronext Paris
PaísFrance
Código postal21121
Telefone33380447500
Sitehttps://inventivapharma.com/
Código da empresaIVA
Data de listagemFeb 15, 2017
CEOMr. Frederic Cren
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Head of Human Resources
Head of Human Resources
--
--
Mr. Frederic Cren
Mr. Frederic Cren
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer, Deputy General Manager
Chief Financial Officer, Deputy General Manager
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Executive Vice President - Regulatory Affairs and Quality Assurance
Executive Vice President - Regulatory Affairs and Quality Assurance
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Dr. Jason Campagna, M.D., Ph.D.
Dr. Jason Campagna, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Head of Human Resources
Head of Human Resources
--
--
Mr. Frederic Cren
Mr. Frederic Cren
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer, Deputy General Manager
Chief Financial Officer, Deputy General Manager
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 17 de abr
Atualizado em: qui, 17 de abr
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Yiheng Capital Management, L.P.
2.76%
New Enterprise Associates (NEA)
1.53%
BVF Partners L.P.
0.72%
Commonwealth Financial Network
0.06%
Wealth Enhancement Advisory Services, LLC
0.02%
Other
94.91%
Investidores
Investidores
Proporção
Yiheng Capital Management, L.P.
2.76%
New Enterprise Associates (NEA)
1.53%
BVF Partners L.P.
0.72%
Commonwealth Financial Network
0.06%
Wealth Enhancement Advisory Services, LLC
0.02%
Other
94.91%
Tipos de investidores
Investidores
Proporção
Investment Advisor
2.84%
Venture Capital
1.53%
Hedge Fund
0.72%
Other
94.91%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
19
4.87M
5.09%
-648.41K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
2023Q3
22
4.86M
11.53%
-1.45M
2023Q2
24
4.83M
11.47%
-1.47M
2023Q1
26
5.13M
12.18%
-904.48K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Yiheng Capital Management, L.P.
2.64M
2.76%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.46M
1.53%
--
--
Mar 31, 2025
BVF Partners L.P.
686.04K
0.72%
--
--
May 07, 2025
Commonwealth Financial Network
54.49K
0.06%
+12.49K
+29.73%
Mar 31, 2025
Wealth Enhancement Advisory Services, LLC
10.71K
0.01%
+10.71K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
4.70K
0%
--
--
May 31, 2025
UBS Financial Services, Inc.
708.00
0%
-608.54K
-99.88%
Mar 31, 2025
BNP Paribas Securities Corp. North America
500.00
0%
-1.40K
-73.68%
Mar 31, 2025
Covestor, Ltd.
402.00
0%
--
--
Mar 31, 2025
Carson Wealth Management Group
--
0%
-100.00
-100.00%
Mar 31, 2024
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
